Opko

The company's revenues for its 4Kscore prostate cancer test were impacted partially by the COVID-19 pandemic, Opko said.

Of the 28 companies in the index, 27 firms saw their stock prices increase, while one firm's share price decreased slightly.

In announcing a national emergency on Friday, Trump paraded out executives from the private sector as the administration tries to increase testing capacity

LabCorp's test is being made available pursuant to FDA guidance that allows high-complexity, CLIA-certified labs to perform their own tests for SARS-CoV-2.

Opko recorded $177.9 million in service revenues, $32 million in product revenues, and $14.4 million from licensing and the transfer of intellectual property revenues.

Most diagnostics companies saw increases in share prices compared to last year, resulting in a significant jump in the 360Dx Index.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.